B. Riley Securities analyst Josh Nichols maintains Synchronoss Technologies (NASDAQ:SNCR) with a Buy and lowers the price target from $2.75 to $2.
Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today?
Edesa Biotech Inc (NASDAQ: EDSA) has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company's first-in-class therapeutic candidate.
